Polyoxometalate-phosphonate Compounds: Synthesis, Structure, Photocatalytic and Antitumor Properties

Xiao-Hui Huang,Xiao-Xing Huang,Shao-Ming Ying,Zhi-Hui Gong,Xiao-Mei Gao,Wen-Chao Bi,Yi-Ping Chen,Yan-Qiong Sun
DOI: https://doi.org/10.1016/j.molstruc.2021.130104
IF: 3.841
2021-01-01
Journal of Molecular Structure
Abstract:Two polyoxometalate-phosphonate compounds with the formular (TBA)2(Hbiz)2 [(C3H5O2P)2Mo5O21]•05H2O (1) and [Ni(2,2′bpy)3]2[(C6H5P)2Mo5O21]•3H2O (2) (TBA=tetrabutylammonium, biz=benzimidazole, bpy=bipyridine) have been synthesized under hydrothermal condition and structurally determined by single-crystal X-ray diffraction. Compound 1 and 2 are Strandberg-type polyoxometalate. The compounds were characterized by various means containing elemental analysis, PXRD, IR and thermal gravimetric analysis. Additionally, their photocatalytic degradation properties toward rhodamine-B are investigated. Compound 2 as catalyst has higher photocatalytic degradation of RhB than 1 due to its larger porosity. Results of the experiment on antitumor activities in vitro showed that two compounds inhibited five different human cancer cells (gastric cancer cells, HGC-27 and SNU668; liver cancer cells, Huh7; and colon cancer cells, HCT116 and SW480) demonstrated dose dependency and selectivity. The relationship between structure and biology activity indicate that inorganic and organic segments may influence the antitumor activity, the introduction of biz and 3-phosphonopropionic acid into P2Mo5 can make compound 1 better antitumor activities.
What problem does this paper attempt to address?